BlossomHill Therapeutics, Inc. (BLSM) AI Stock Analysis

17 Followers

BlossomHill Therapeutics, Inc.

(NASDAQ:BLSM)

Select Model

Rating:49Neutral

Price Target:$13.50▼(-5.20% Downside)

Action:reiterated

Date:10/07/26

The score is held down primarily by weak financial performance (no revenue, widening losses, rising cash burn, and deeply negative equity). Technical indicators also point to weak momentum with the price below its 20-day average and negative MACD. Offsetting these risks, recent corporate events are positive, highlighted by encouraging clinical-trial response rates and an IPO that added capital.

Positive Factors

Regulatory ProgressFDA alignment on the recommended dose and a registrational-intent Phase 2 design materially advances BH-30643 beyond early development. Progress toward a defined trial supports regulatory execution and creates a clearer path to potential approval in an underserved resistance setting.

Negative Factors

No Commercial RevenueA lack of revenue means the company currently has no commercial cash engine to fund operations or offset research spending. Its path to breakeven therefore depends on successful clinical development, regulatory progress, and future commercialization or partnerships.

BlossomHill Therapeutics, Inc. (BLSM) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $414.12M
Dividend Yield: ―
Average Volume (3M): 197.08K
Price to Earnings (P/E): -1.5
Beta (1Y): 0.88
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 69
Sector: General
Sector Strength: 55
Industry: Biotechnology

BlossomHill Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

BlossomHill Therapeutics, Inc. Financial Statement Overview

Summary

Financial statements are weak overall: no revenue in 2024–2025, losses widened materially (net loss roughly -$30.7M to -$60.6M), and cash burn increased (operating cash flow about -$31.4M to -$46.9M). Balance-sheet quality is pressured by deeply negative and worsening equity (about -$72.9M to -$131.7M) and rising debt (about $0.5M to $22.4M), despite higher total assets.

Income Statement

12Very Negative

Balance Sheet

22Negative

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024
Income Statement
Total Revenue	0	0	0
Gross Profit	0	0	0
EBITDA	-46.65M	-63.58M	-36.05M
Net Income	-44.77M	-60.55M	-30.70M
Balance Sheet
Total Assets	124.13M	162.97M	106.78M
Cash, Cash Equivalents and Short-Term Investments	95.38M	136.68M	100.15M
Total Debt	23.37M	22.40M	525.00K
Total Liabilities	42.09M	294.70M	179.66M
Stockholders Equity	82.04M	-131.73M	-72.88M
Cash Flow
Free Cash Flow	-44.19M	-47.99M	-31.51M
Operating Cash Flow	-44.17M	-46.92M	-31.42M
Investing Cash Flow	-13.00K	-1.07M	-92.00K
Financing Cash Flow	2.88M	84.53M	17.56M

BlossomHill Therapeutics, Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

BLSM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
BLSM	49Neutral	$452.62M	-1.50	127.76%	―	―	―
FTH	46Neutral	$333.90M	-0.09	-153.55%	―	―	-624.45%
IVA	46Neutral	$897.29M	-6.34	-1625.48%	―	-99.61%	66.37%
FDMT	44Neutral	$688.34M	-4.58	-41.33%	―	278712.12%	26.59%
CADL	42Neutral	$715.45M	-6.63	-89.38%	―	―	-108.75%
OLMA	41Neutral	$636.11M	-3.08	-53.67%	―	―	-29.91%

* General Sector Average

Performance Comparison

BLSM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
BLSM	BlossomHill Therapeutics, Inc.	14.24	-1.76	-11.00%
IVA	Inventiva SA ADR	3.95	-0.10	-2.47%
OLMA	Olema Pharmaceuticals, Inc.	7.27	-0.79	-9.80%
FDMT	4D Molecular Therapeutics, Inc.	12.46	1.49	13.58%
FTH	Faeth Therapeutics, Inc.	12.92	2.82	27.92%
CADL	Candel Therapeutics, Inc.	9.35	4.43	90.04%

BlossomHill Therapeutics, Inc. Corporate Events

Business Operations and StrategyProduct-Related Announcements

BlossomHill updates BH-30643 lung cancer trial results

Positive

Sep 15, 2026

On September 15, 2026, BlossomHill Therapeutics reported updated results from its ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer patients with secondary EGFR resistance mutations such as C797S. The data were showcased in a m...

Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance

BlossomHill Therapeutics completes IPO and updates governance

Positive

Aug 10, 2026

On August 10, 2026, BlossomHill Therapeutics, Inc. closed its initial public offering of 9,375,000 shares of common stock at $16.00 per share, generating approximately $150.0 million in gross proceeds before underwriting discounts, commissions and of...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 07, 2026

BlossomHill Therapeutics, Inc. AI Stock Analysis